Sunitinib, Cyclophosphamide, and Methotrexate in Treating Patients With Metastatic Breast Cancer

• Status: Terminated
• Trial end date: 2012-12-01
• Target enrollment: 0
• Participant gender: All

Summary

RATIONALE: Sunitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as cyclophosphamide and methotrexate, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving sunitinib together with combination chemotherapy may kill more tumor cells.

PURPOSE: This phase I/II trial is studying the side effects and best dose of sunitinib when given together with cyclophosphamide and methotrexate to see how well they work in treating patients with metastatic breast cancer.

• Phase: Phase 1/Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of California, San Francisco
• Collaborator: National Cancer Institute (NCI)
• Treatments: Cyclophosphamide; Methotrexate; Sunitinib

Criteria

DISEASE CHARACTERISTICS:

• Pathologically confirmed diagnosis of breast cancer with documented progressive disease

• Metastatic disease

• Measurable disease as defined by RECIST criteria or evaluable disease

• Must have received at least one prior chemotherapy regimen for metastatic breast cancer

• Patients refusing all other chemotherapy for breast cancer may enroll without prior treatment

• Patients with HER2-overexpression disease must have been previously treated with trastuzumab (Herceptin®)

• Patients with stable brain metastases are eligible

• Hormone receptor status not specified

PATIENT CHARACTERISTICS:

• Menopausal status not specified

• Eastern Cooperative Oncology Group (ECOG) performance status 0-2

• Life expectancy ≥ 12 weeks

• Absolute Neutrophil Count (ANC) ≥ 1,000/mm³

• Platelet count ≥ 100,000/mm³

• Creatinine ≤ 1.5 times upper limit of normal (ULN)

• aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 times ULN (≤ 5 times ULN in the presence of liver metastases)

• Total bilirubin ≤ 1.5 times ULN

• Able to take oral medications and maintain hydration

• Not pregnant or nursing

• Negative pregnancy test

• Fertile patients must use effective contraception during and for 6 months after treatment

• No severe concurrent illness including, but not limited to, any of the following:

• Congestive heart failure

• Significant cardiac disease

• Uncontrolled hypertension

• Must be able to read and speak English

PRIOR CONCURRENT THERAPY:

• See Disease Characteristics

• At least 2 weeks since prior treatment, including chemotherapy, hormonal therapy, trastuzumab (Herceptin®), or other targeted therapies

• Prior bevacizumab allowed if discontinued for any reason other than toxicity

• No potent inducers or inhibitors of CYP3A4 enzymes that effect the metabolism of sunitinib malate

• No prior sunitinib malate

• No other concurrent investigational therapy

• No concurrent radiotherapy

• Concurrent bisphosphonates allowed